Are mast cells still important in asthma?

Revue Francaise d'Allergologie et d'Immunologie Clinique

Volumn 42, Issue 1, 2002, Pages 20-27

  Barnes, P J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR; ALLERGEN; ARACHIDONIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CD23 ANTIGEN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYTOKINE; FLUTICASONE; FORMOTEROL; FUROSEMIDE; GROWTH FACTOR; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; LACTOFERRIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; N (1 HYDROXY 2 NAPHTHOYL)ARGINYLPROLINAMIDE; OMALIZUMAB; PEPTIDOLEUKOTRIENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR; SALMETEROL; SLOW REACTING SUBSTANCE; TRANSCRIPTION FACTOR; UNINDEXED DRUG;

ASTHMA; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; MAST CELL; NONHUMAN;

EID: 0036150007     PISSN: 03357457     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0335-7457(01)00108-3     Document Type: Conference Paper

References (95)

1. Inflammatory mediators of asthma: An update
2. Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells
3. Dexamethasone does not inhibit the release of mediators from human lung mast cells residing in airway, intestine or skin
4. Antiinflammatory actions of glucocorticoids: Molecular mechanisms
5. Effect of beta agonists on inflammatory cells
6. Anti-IgE therapy in asthma: Rationale and therapeutic potential
7. The pathophysiology of human mast cells. In vitro and in vivo function
8. The stem cell factor, its properties and potential role in the airways
9. The kit ligand, stem cell factor
10. Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma
11. Effect of an inhaled corticosteroid on airway inflammation and symptoms of asthma
12. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: In vitro and in vivo evidence in murine systems
13. Glucocorticoid suppresses autocrine survival of mast cells by inhibiting IL-4 production and ICAM-1 expression
14. Cytokines in asthma
15. Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in late-phase allergic reactions in the lung and skin
16. Elevated bronchoalvolear lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness
17. Effects of antihistamines in adult asthma: A meta-analysis of clinical trials
18. Immunologic and neuropharmacologic stimulation of mucous glycoprotein release from human airways in vitro
19. Effect of histamine on human bronchial arteries in vitro
20. 3-receptors modulate antigen-induced bronchoconstriction in guinea pigs
21. Mast cell mediators prostaglandin D2 and histamine activate human eosinophils
22. The role of leukotrienes in inflammation
23. Treatment of asthma with drugs modifying the leukotriene pathway
24. The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma
25. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
26. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects
27. 4 following allergen challenge and in patients with acute asthma and allergic rhinitis
28. Prostaglandin D2 as a mediator of allergic asthma
29. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2
30. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor
31. 2 inhibits multiple steps in the NF-κB signaling pathway
32. Novel antiinflammatory targets for asthma. A role for PPARγ?
33. Mast cells as a source of multi-functional cytokines
34. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease
35. Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-alpha in sensitized lung tissue after IgE receptor triggering
36. Tumor necrosis factor-α increases airway responsiveness and sputum neutrophils in normal human subjects
37. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics
38. Human lung mast cell IL-5 gene and protein expression: Temporal analysis of upregulation following IgE-mediated activation
39. IL-4 and -5 prime human mast cells for different profiles of IgE-dependent cytokine production
40. T helper cell type 2 cytokine-mediated comitogenic responses and mLR3 expression during differentiation of human mast cells in vitro
41. Mast cells
42. Interleukin-10 is localized to and released by human lung mast cells
43. Inhibition of IgE-induced activation of human mast cells by IL-10
44. Interleukin-10: A key regulator of allergic disease
45. Neurotrophins and asthma
46. Human mast cells express functional TrkA and are a source of nerve growth factor
47. Nerve growth factor: An important molecule in allergic inflammation and tissue remodelling
48. IgE receptor-mediated release of nerve growth factor by mast cells
49. Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma
50. Local increase in the number of mast cells and expression of nerve growth factor in the bronchus of asthmatic patients after repeated inhalation of allergen at low-dose
51. Interactions of mast cell tryptase with thrombin receptors and PAR-2
52. Proteinase-activated receptors: Novel mechanisms of signaling by serine proteases
53. Mast cell tryptase potentiates histamine-induced contraction in human sensitized bronchus
54. Protease inhibitors potentiate smooth muscle relaxation induced by vasoactive intestinal peptide in isolated human bronchi
55. Inhaled tryptase causes bronchoconstriction in sheep via histamine release
56. Tryptase, the dominant secretory granular protein in human mast cells, is a potent mitogen for cultured dog tracheal smooth muscle cells
57. Human mast cell tryptase: A stimulus of microvascular leakage and mast cell activation
58. Granulocyte recruitment by human mast cell tryptase
59. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts
60. Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression
61. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma
62. Cell infiltration, ICAM-1 expression, and eosinophil chemotactic activity in asthmatic sputum
63. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep
64. Lactoferrin, a potent tryptase inhibitor, abolishes late-phase airway responses in allergic sheep
65. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma
66. A comparison of the osmotic activation of basophils and human lung mast cells
67. Pharmacological characterization of adenosine A2B receptors: Studies in human mast cells co-expressing A2A and A2B adenosine receptor subtypes
68. Mechanism of airway hyperresponsiveness to adenosine induced by allergen challenge in actively sensitized Brown Norway rats
69. 2B receptors: A novel therapeutic target in asthma?
70. ATP modulates anti-IgE-induced release of histamine from human lung mast cells
71. Characterisation of the receptor mediating antianaphylactic effects of β-adrenoceptor agonists in human lung tissues in vitro
72. Formoterol on airway smooth muscle and human lung mast cells: A comparison with salbutamol and salmeterol
73. Functional desensitization of beta agonist responses in human lung mast cells
74. Salmeterol inhibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independent mechanisms
75. 2-agonists
76. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma
77. Influence of receptor reserve on beta-adrenoceptor-mediated responses in human lung mast cells
78. 2-adrenergic receptor
79. 2-adrenergic receptors desensitize in response to in vivo administered β-agonist
80. 2-agonists
81. Regular inhaled salbutamol and airway responsiveness to allergen
82. Protection by dexamethasone of the functional desensitization to beta 2- adrenoceptor-mediated responses in human lung mast cells
83. 2-agonists and corticosteroids
84. Effect of inhaled formoterol and budesonide on exacerbations of asthma
85. Exacerbations of asthma. A descriptive study of 425 severe exacerbations
86. Up- and down-regulation by glucocorticoids of the constitutive expression of the mast cell growth factor stem cell factor by human lung fibroblasts in culture
87. Pharmacology of sodium cromoglycate
88. Chloride transport and the action of sodium cromoglycate and nedocromil sodium in asthma
89. Reducing IgE levels as a strategy for the treatment of asthma
90. The effect of an anti-IgE monoclonal antibody on the early and late phase responses to allergen inhalation in asthmatic subjects
91. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
92. Treatment of allergic asthma with monoclonal anti-IgE antibody
93. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
94. Inhaled loop diuretics as potential new anti-asthmatic drugs
95. Effect of acute and chronic inhaled furosemide on bronchial hyperresponsiveness in mild asthma